Suppression of antitumor immune responses is one of the main mechanisms by which tumor
cells escape from destruction by the immune system. Myeloid-derived suppressor cells …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–
targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such …

The continuous remodeling of the tumor microenvironment (TME) during prostate
tumorigenesis is emerging as a critical event that facilitates cancer growth, progression and …

Prostate cancer (PC) remains a leading cause of cancer-related deaths among men
worldwide, despite continuously improved treatment strategies. Patients with metastatic …

Therapeutic interventions for advanced prostate cancer (PCa) center on inhibiting androgen
receptor (AR) and downstream signaling pathways. Resistance to androgen deprivation …

Representative in vitro model systems that accurately model response to therapy and allow
the identification of new targets are important for improving our treatment of prostate cancer …

It is well known that genetic mutations can drive drug resistance and lead to tumor relapse.
Here, we focus on alternate mechanisms—those without mutations, such as phenotypic …

Androgen deprivation therapy or ADT is one of the cornerstones of management of locally
advanced or metastatic prostate cancer, alongside radiation therapy. However, despite early …

The role of endocrine disruptors (EDs) in the human prostate gland is an overlooked issue
even though the prostate is essential for male fertility. From experimental models, it is known …